ArticleFrontiers in pediatrics2026
A retrospective cross-sectional study on newborn screening and prevalence of disorders among UAE population.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Newborn screening (NBS) is a crucial public health initiative designed to detect genetic, metabolic, and endocrine disorders in infants before clinical symptoms appear. Early detection enables timely intervention, reducing morbidity and mortality associated with congenital diseases. Objective: This study aimed to determine the prevalence of common disorders detected through newborn screening among the United Arab Emirates (UAE) population from year 2021 to 2023. Methods: A retrospective cross-sectional study was conducted using newborn screening data collected from the National Reference Laboratory (NRL), representing samples from 20 hospitals and laboratories across Abu Dhabi, Dubai, Sharjah, and Fujairah. Screening tests included hemoglobinopathies, aminoacidopathies, acylcarnitine disorders, cystic fibrosis, glucose-6-phosphate dehydrogenase (G6PD) deficiency, congenital hypothyroidism (CH), congenital adrenal hyperplasia (CAH), biotinidase deficiency, and galactose-1-phosphate uridylyltransferase (GALT) deficiency. Prevalence was calculated per 100,000 screened newborns using SPSS, excluding inconclusive and false-positive cases. Results: Of 29,290 newborns screened, 2,191 (7.4%) were positive for one or more disorders, and 698 (2.3%) were identified as hemoglobinopathy carriers. The highest prevalence was observed for G6PD deficiency (5,278 per 100,000 screened newborns), followed by cystic fibrosis (566 per 100,000 screened newborns), acylcarnitine disorders (518 per 100,000 screened newborns), and aminoacidopathies (505 per 100,000 screened newborns). Endocrine disorders, including CAH (160 per 100,000 screened newborns) and CH (116 per 100,000 screened newborns), were also detected. Hemoglobinopathies, particularly alpha-thalassemia and sickle cell anemia, represented the most common inherited blood disorders. Conclusion: The findings highlight a significant burden of G6PD deficiency and other metabolic disorders among newborns in the UAE. The study underscores the importance of continuous monitoring, expanded screening panels, and genetic counseling for carrier detection to improve neonatal outcomes and guide public health strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.